These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 15040478)

  • 1. Serum levels of autoantibodies to desmoglein 3 in patients with therapy-resistant pemphigus vulgaris successfully treated with adjuvant intravenous immunoglobulins.
    Herzog S; Schmidt E; Goebeler M; Bröcker EB; Zillikens D
    Acta Derm Venereol; 2004; 84(1):48-52. PubMed ID: 15040478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of intravenous immunoglobulin therapy on autoantibody titers to desmoglein 3 and desmoglein 1 in pemphigus vulgaris.
    Sami N; Bhol KC; Ahmed RA
    Eur J Dermatol; 2003; 13(4):377-81. PubMed ID: 12948919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic features of pemphigus vulgaris in patients with pemphigus foliaceus: detection of both autoantibodies, long-term follow-up and treatment responses.
    Sami N; Bhol KC; Ahmed AR
    Clin Exp Immunol; 2001 Sep; 125(3):492-8. PubMed ID: 11531959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of IVIg therapy on autoantibody titers to desmoglein 1 in patients with pemphigus foliaceus.
    Sami N; Bhol KC; Ahmed AR
    Clin Immunol; 2002 Nov; 105(2):192-8. PubMed ID: 12482393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous immunoglobulin selectively decreases circulating autoantibodies in pemphigus.
    Czernik A; Beutner EH; Bystryn JC
    J Am Acad Dermatol; 2008 May; 58(5):796-801. PubMed ID: 18423257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Intravenous immunoglobulin therapy: ELISA measurement of antidesmogleins 1 and 3 in three patients with pemphigus vulgaris].
    Suárez-Fernández R; Longo I; Avilés JA; Bueno C; Rodríguez-Mahou M; Lázaro P
    Rev Clin Esp; 2006 Nov; 206(10):499-503. PubMed ID: 17129517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pemphigus.
    Kasperkiewicz M; Ellebrecht CT; Takahashi H; Yamagami J; Zillikens D; Payne AS; Amagai M
    Nat Rev Dis Primers; 2017 May; 3():17026. PubMed ID: 28492232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Juvenile pemphigus vulgaris].
    Janisson-Dargaud D; Reguiaï Z; Perceau G; Eschard C; Bernard P
    Ann Dermatol Venereol; 2008 Dec; 135(12):843-7. PubMed ID: 19084695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neonatal pemphigus vulgaris: IgG4 autoantibodies to desmoglein 3 induce skin blisters in newborns.
    Parlowsky T; Welzel J; Amagai M; Zillikens D; Wygold T
    J Am Acad Dermatol; 2003 Apr; 48(4):623-5. PubMed ID: 12664033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of intravenous immunoglobulin therapy on serum levels of IgG1 and IgG4 antidesmoglein 1 and antidesmoglein 3 antibodies in pemphigus vulgaris.
    Green MG; Bystryn JC
    Arch Dermatol; 2008 Dec; 144(12):1621-4. PubMed ID: 19075146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic features of pemphigus vulgaris in patients with bullous pemphigoid. Molecular analysis of autoantibody profile.
    Sami N; Bhol KC; Beutner EH; Plunkett RW; Leiferman KM; Ahmed AR
    Dermatology; 2002; 204(2):108-17. PubMed ID: 11937735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prolonged complete clinical remission in patients with severe pemphigus vulgaris after cycles of intravenous cyclophosphamide].
    España Alonso A; Panizo C; Fernández S; Marquina M; Pretel M; Aguado L; Sánchez-Ibarrola A
    Actas Dermosifiliogr; 2009 Mar; 100(2):113-20. PubMed ID: 19445875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pemphigus vulgaris: update on etiopathogenesis, oral manifestations, and management.
    Scully C; Challacombe SJ
    Crit Rev Oral Biol Med; 2002; 13(5):397-408. PubMed ID: 12393759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of pemphigus with intravenous immunoglobulin.
    Bystryn JC; Jiao D; Natow S
    J Am Acad Dermatol; 2002 Sep; 47(3):358-63. PubMed ID: 12196744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IVIg selectively and rapidly decreases circulating pathogenic autoantibodies in pemphigus vulgaris.
    Bystryn JC; Jiao D
    Autoimmunity; 2006 Nov; 39(7):601-7. PubMed ID: 17101504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis and treatment of pemphigus.
    Tsuruta D; Ishii N; Hashimoto T
    Immunotherapy; 2012 Jul; 4(7):735-45. PubMed ID: 22853759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Adjuvant therapy of pemphigus vulgaris and pemphigus foliaceus with intravenous immunoglobulins].
    Enk AH; Knop J
    Hautarzt; 1998 Oct; 49(10):774-6. PubMed ID: 9857253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Successful treatment of corticoid-resistant pemphigus with high-dose intravenous immunoglobulins].
    Sibaud V; Beylot-Barry M; Doutre MS; Beylot C
    Ann Dermatol Venereol; 2000 Apr; 127(4):408-10. PubMed ID: 10844264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Detection of serum desmoglein antibody level using enzyme-linked immunosorbent assay (ELISA) for monitoring disease activity in patients with pemphigus vulgaris].
    Zhong S; Qiu YF; Han BB; Zhao JY; Zhu XJ; Chen XX
    Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Jun; 43(3):414-5. PubMed ID: 21681274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective Plasma Exchange for the Removal of Pemphigus Autoantibodies, Fibrinogen, and Factor XIII in Pemphigus Vulgaris.
    Miyamoto S; Ohkubo A; Seshima H; Komori S; Yamamoto M; Maeda T; Itagaki A; Yamamoto H; Nojima K; Iimori S; Naito S; Kurashima N; Sohara E; Rai T; Uchida S; Okado T
    Ther Apher Dial; 2017 Jun; 21(3):226-231. PubMed ID: 28661086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.